Free Trial
NASDAQ:OKUR

OnKure Therapeutics (OKUR) Stock Price, News & Analysis

OnKure Therapeutics logo
$2.75 +0.06 (+2.23%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.74 -0.01 (-0.36%)
As of 09/5/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About OnKure Therapeutics Stock (NASDAQ:OKUR)

Key Stats

Today's Range
$2.61
$2.75
50-Day Range
$2.00
$2.83
52-Week Range
$1.70
$20.00
Volume
20,763 shs
Average Volume
123,878 shs
Market Capitalization
$37.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.33
Consensus Rating
Buy

Company Overview

OnKure Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

OKUR MarketRank™: 

OnKure Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 453rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OnKure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    OnKure Therapeutics has a consensus price target of $32.33, representing about 1,075.8% upside from its current price of $2.75.

  • Amount of Analyst Coverage

    OnKure Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about OnKure Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for OnKure Therapeutics are expected to grow in the coming year, from ($4.05) to ($3.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OnKure Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OnKure Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    OnKure Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about OnKure Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for OKUR.
  • Dividend Yield

    OnKure Therapeutics does not currently pay a dividend.

  • Dividend Growth

    OnKure Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for OKUR.
  • Search Interest

    Only 3 people have searched for OKUR on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added OnKure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OnKure Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $931.00 in company stock.

  • Percentage Held by Insiders

    Only 2.30% of the stock of OnKure Therapeutics is held by insiders.

  • Percentage Held by Institutions

    90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OnKure Therapeutics' insider trading history.
Receive OKUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OnKure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OKUR Stock News Headlines

HC Wainwright Has Optimistic Outlook of OKUR Q3 Earnings
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Headlines

OKUR Stock Analysis - Frequently Asked Questions

OnKure Therapeutics' stock was trading at $8.60 at the start of the year. Since then, OKUR shares have decreased by 68.0% and is now trading at $2.75.

OnKure Therapeutics, Inc. (NASDAQ:OKUR) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.09.

OnKure Therapeutics' top institutional investors include Acorn Capital Advisors LLC (21.02%), Shay Capital LLC (5.79%), Highbridge Capital Management LLC (4.91%) and Affinity Asset Advisors LLC (2.58%). Insiders that own company stock include Jason A Leverone and Nicholas A Saccomano.
View institutional ownership trends
.

Shares of OKUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/12/2025
Today
9/06/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OKUR
Previous Symbol
NASDAQ:OKUR
CIK
1637715
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$34.00
Low Price Target
$30.00
Potential Upside/Downside
+1,075.8%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$52.67 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-60.52%
Return on Assets
-55.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.13
Quick Ratio
11.13

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.78 per share
Price / Book
0.35

Miscellaneous

Outstanding Shares
13,530,000
Free Float
13,219,000
Market Cap
$37.21 million
Optionable
N/A
Beta
0.43
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:OKUR) was last updated on 9/6/2025 by MarketBeat.com Staff
From Our Partners